HHS loses in court over fixed indemnity insurance rule

The U.S. Court of Appeals for the District of Columbia ruled that HHS can’t limit the sale of fixed indemnity insurance plans as only a supplement to coverage that meets Affordable Care Act standards.

The New York Times said the court labeled the HHS rule as an “administrative overreach.”

For more on why HHS decided to go after fixed indemnity plans with its 2014 rule, and why some states argue it should be an acceptable alternative to ACA-compliant plans, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.